esaxerenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists | 5490 | 1632006-28-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Esaxerenone is an oral, selective nonsteroidal mineralocorticoid receptor antagonist used for the treatment of hypertension and diabetic nephropathies.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 1, 2021 | PMDA | DAIICHI SANKYO COMPANY, LIMITED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertension | indication | 38341003 | DOID:10763 |
| Diabetic nephropathy | indication | 127013003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mineralocorticoid receptor | Nuclear hormone receptor | ANTAGONIST | IC50 | 8.43 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| E6R | PDB_CHEM_ID |
| CHEMBL3545393 | ChEMBL_ID |
| C000607547 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9894 | IUPHAR_LIGAND_ID |
| DB15207 | DRUGBANK_ID |
| D10892 | KEGG_DRUG |
| C5139864 | UMLSCUI |
| 10230 | INN_ID |
| 25052023 | PUBCHEM_CID |
| N62TGJ04A1 | UNII |
Pharmaceutical products:
None